Immunogenicity, breakthrough infection, and underlying disease flare after SARS-CoV-2 vaccination among individuals with systemic autoimmune rheumatic diseases

Many patients with systemic autoimmune rheumatic diseases (SARDs) require immunosuppression to reduce disease activity, but this also has important possible detrimental impacts on immune responses following vaccination. The phase III clinical trials for severe acute respiratory syndrome coronavirus...

Descripción completa

Detalles Bibliográficos
Autores principales: Paik, Julie J., Sparks, Jeffrey A., Kim, Alfred H.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058024/
https://www.ncbi.nlm.nih.gov/pubmed/35636384
http://dx.doi.org/10.1016/j.coph.2022.102243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058024/
https://www.ncbi.nlm.nih.gov/pubmed/35636384
http://dx.doi.org/10.1016/j.coph.2022.102243

Ejemplares similares